Tao Yang, Hang Ke, Jinping Liu, Xiaoyu An, Jia Xue, Jinying Ning, Feng Hao, Lingxin Xiong, Cen Chen, Yueying Wang, Jia Zheng, Bing Gao, Zhengzheng Bao, Kefeng Gong, Lei Zhang, Faming Zhang, Sheng Guo, Qi-Xiang Li
CSF1R is a receptor tyrosine kinase responsible for the growth/survival/polarization of macrophages and overexpressed in some AML patients. We hypothesized that a novel multi-kinase inhibitor (TKi), narazaciclib (HX301/ON123300), with high potency against CSF1R (IC50 ~ 0.285 nM), would have anti-AML effects. We tested this by confirming HX301's high potency against CSF1R (IC50 ~ 0.285 nM), as well as other kinases, e.g. FLT3 (IC50 of ~ 19.77 nM) and CDK6 (0...
April 19, 2024: Scientific Reports